Northeast Wisconsin Retina Associates

05/26/2026

Our practice is dedicated to treating retinal disorders, offering care from seven specialists across six convenient locations. With decades of combined experience serving Northeastern Wisconsin and Upper Michigan, we remain committed to helping patients protect their vision. Learn more: https://brnw.ch/21x2PHR

05/21/2026

Testimonials like these remind us why we do what we do. We’re grateful to provide care and support to our patients every step of the way.

05/19/2026

Ocugen’s investigational gene therapy, OCU410, showed promising results in reducing geographic atrophy progression in patients with dry age-related macular degeneration. The therapy demonstrated safety and structural benefits, supporting plans for a Phase 3 trial later in 2026. Learn more: https://brnw.ch/21x2CI5

Phase 2 ArMaDa data show statistically significant 31% reduction in GA lesion growth with OCU410 at 12 months, with a favorable safety profile supporting phase 3 development.

05/14/2026

The first quarter of 2026 saw important advancements in ophthalmology, including treatments for presbyopia, age-related macular degeneration, dry eye disease, glaucoma, corneal dystrophy, and geographic atrophy. New technologies are helping improve patient care. Learn more: https://brnw.ch/21x2ufC

Q1 2026 eye-care roundup: first dual-agent presbyopia drop, new EDOF IOL, wet AMD phase 3 win, and gene-therapy advances.

05/12/2026

Our North Fond du Lac Retina Center provides care for patients across Northeastern Wisconsin and Upper Michigan. We offer comprehensive diagnosis and treatment for a wide range of retinal conditions. Learn more: https://brnw.ch/21x2pYa

05/07/2026

Vitrectomy is an advanced eye surgery that helps treat serious retinal conditions, like retinal tears and macular holes. Our specialists at Northeast Wisconsin Retina Associates provide expert care throughout the entire process. Learn more: https://brnw.ch/21x2hcM

05/05/2026

Regular anti-VEGF injections help protect vision by controlling abnormal blood vessel growth and reducing swelling in the eye. Consistent treatment and follow-up with a retina specialist are key to maintaining long-term eye health. Learn more: https://brnw.ch/21x2cSs

04/30/2026

Ocugen has completed enrollment in a Phase 3 clinical trial studying OCU400, a potential gene therapy for retinitis pigmentosa. This milestone marks an important step forward in research aimed at expanding future treatment options for people living with this rare eye condition. Learn more: https://brnw.ch/21x24KC

The company describes liMeliGhT as a 1-year clinical trial that will support the Biologics License Application (BLA) filing for OCU400 and potential approval in 2027.

04/28/2026

Have questions or need to schedule an appointment with Northeast Wisconsin Retina Associates? Our team is here to help at any of our convenient locations throughout Northeast Wisconsin. Learn more: https://brnw.ch/21x20sf

04/23/2026

Age-related macular degeneration (AMD) is a leading cause of vision loss, but early detection can make a meaningful difference. Because symptoms often develop gradually, routine eye exams are key to catching changes before they impact your daily life. Staying proactive about your eye health can help protect your vision for the future. Learn more: https://brnw.ch/21x1RBZ

AMD affects vision over time, but early detection is key to managing its progression. Learn about early symptoms and how to protect your vision here.

04/21/2026

We’re grateful for the kind words shared about the team at Northeast Wisconsin Retina Clinic. Hearing that our staff felt professional and welcoming, and that Dr. Hejny took time to explain care clearly, means a great deal to us. It’s a privilege to care for our patients and their vision every day.